REVIVO BioSystems Pte. Ltd.
100 Tras Street
#09-01, 100 AM
Singapore 079027

Financial

Our Company and business model

REVIVO BioSystems is building a human-relevant preclinical testing platform at the intersection of non-animal methods, organ-on-chip automation, engineered tissue models and longitudinal biomarker analytics. The commercial plan is to use CRO services as the wedge: services generate revenue, validate applications with strategic accounts, create protocols and pull customers toward in-lab adoption of Rele*GO* platforms, REV*tissues* kits and REV*analytics*.

The near-term business is a hybrid of services, hardware and consumables, while REV*analytics* begins as an add-on subscription and becomes a higher-margin data layer over time. The platform is designed to create ARR-like repeatability once readers, kits and analytics are installed in customer labs.

The Series A plan is framed around value inflection: launch productized REV*tissues* (especially REV*fibr* kits) and the Rele*GO Reader*, establish the EU commercialization/production foothold, complete KOL and validation packages, and build enough product/software momentum to support a Series B or strategic partnership process by 2028.

Current commercial proof	US$1.6M cumulative revenue, >30 CRO service deals and 15 ReleGO sold, with blue-chip traction across personal care, pharma/biopharma and wound care.
Base-case forecast	Revenue grows from US$0.54M in 2025 to US$7.17M in 2028.
Breakeven path	Financial sustainability of the current team and operations will be achieved in 2026. Annual Profit Before Tax (PBT) turns positive in 2028 and becomes structurally profitable from 2029 onward.

Financial Summary

REVIVO BioSystems is transitioning from early commercial validation to scale-up. 2025 revenue was approximately US$0.54M, and 2026 base-case revenue is forecast at approximately US$0.92M. Revenue is still driven largely by services and early product placements. We have already developed a first prototype of the REV*analytics* for permeation tests, which will be expanded to ELISA results analysis as well: software revenue therefore begins to appear in 2026 and will become material from 2028 onward.

Projected budget of the organization for 2026 and 2027

24-month budget by accounting category

Category	Budget (US$m)	Share of budget	Purpose
Manpower/team expansion	2.01	50.2%	Expand from core team to minimum operating team across management, BD, bio-R&D,

Category	Budget (US$m)	Share of budget	Purpose
			hardware/software, quality and interns.
Product development	1.29	32.4%	REV*fibr* reproducible line, Rele*GO Reader* upgrades, *fibr* enabled ready-to-use kits, REV*analytics* MVP and data-platform hardening.
Lab & office	0.28	7.0%	Singapore lab/office, EU lab rental and core lab assets including plate reader.
Sales & marketing	0.25	6.2%	Business trips, trade shows, seminars, conferences, digital marketing, KOLs, demos and customer training.
Other/IP/legal/regulatory	0.17	4.3%	Consultancy, regulatory work, IP, legal, insurance, accounting, licensing fees, loan repayments and banking fees.

24-month budget by strategic buckets

Category	Budget (US$m)	Share of budget	Purpose
Product & Technology	1.6	40%	Rele*GO Reader*, testing tissue kits, REV*fibr*/*fibr* biomarkers validation, REV*analytics* beta, workflow integration, microfluidic chips upgrades
Commercialization & EU Expansion	1.2	30%	EU office/lab, sales hires, CRO service scale-up, sales channel expansion, demos and market development
Validation & Regulatory Readiness	0.8	20%	KOL studies, biomarker validation, publications, OECD/USP/ISTAND readiness, GLP/GMP/QMS foundation
Runway, IP & G&A	0.4	10%	IP protection, legal, compliance, insurance, finance/admin buffer and working capital

REVIVO BioSystems Pte. Ltd.
100 Tras Street
#09-01, 100 AM
Singapore 079027

Financial forecasts / projections

Forecasted revenues, COGS, expenses, margin

	in Million USD	2026	2027	2028
1	Total Revenue/Income	0.92	2.59	7.17
	Services	0.47	1.29	2.39
	Products	0.44	1.24	4.34
	Software/REV*analytics*	-	0.06	0.43
2	COGS	0.32	0.95	2.37
3	Gross Margin	0.59	1.64	4.80
4	Operating Expenses	0.87	2.32	2.86
5	Profit before taxes	(0.28)	(0.68)	1.94